This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Luminex (LMNX) Product Portfolio Solid, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) flagship VERIGENE and ARIES systems are likely to boost its growth trajectory.
Why Is Luminex (LMNX) Up 11.2% Since Its Last Earnings Report?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Banks on Solid Product Line, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Luminex's (LMNX) favorable tidings at the regulatory front in Q4 buoy optimism.
ResMed (RMD) Rides on Product Launches, Robust Global Growth
by Zacks Equity Research
ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) Specialty Health unit is likely to drive the company's top line in the third quarter of fiscal 2018.
What's in Store for Becton, Dickinson (BDX) in Q1 Earnings?
by Zacks Equity Research
Despite solid prospects in the emerging markets, Becton, Dickinson (BDX) is likely to witness sluggishness in BD Medical and BD Life Sciences in Q1.
Abbott Rides High on FDA Approvals & Buyouts Amid Headwinds
by Zacks Equity Research
Abbott (ABT) appears to gain traction from the current integration and synergy achievement of St. Jude. Meanwhile, the company's recent closure of Alere takeover is another positive.
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter (BAX) has been gaining on the back of favorable developments in the regulatory front and product launches.
Abbott (ABT) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.